JoinClinicalTrials.com

• Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

  NCT03764228

  Condition:   Acute-graft-versus-host Disease
  Intervention:   Biological: hAECs
  Sponsors:   Peking University People's Hospital;   Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
  Not yet recruiting
• A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease

  NCT03605940

  Condition:   Acute-graft-versus-host Disease
  Interventions:   Combination Product: Methoxsalen + ECP device;   Drug: Corticosteroids
  Sponsor:   Central Hospital, Nancy, France
  Not yet recruiting
• Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

  NCT03497273

  Condition:   Acute Graft-versus-host Disease
  Interventions:   Drug: Itacitinib;   Drug: Corticosteroid
  Sponsor:   Incyte Corporation
  Recruiting
• Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

  NCT02133924

  Condition:   Acute Graft Versus Host Disease
  Interventions:   Drug: natalizumab;   Drug: steroids
  Sponsors:   John Levine;   Biogen
  Recruiting
• Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease

  NCT03327857

  Condition:   Steroid-refractory Acute Graft-versus-Host Disease
  Intervention:   Biological: AbGn-168H
  Sponsor:   AbGenomics International, Inc.
  Recruiting
• An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

  NCT03339297

  Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
  Interventions:   Drug: Defibrotide;   Drug: Standard of Care
  Sponsor:   Jazz Pharmaceuticals
  Recruiting
• T-Guard as Treatment for Steroid Refractory Acute GVHD

  NCT04128319

  Condition:   Steroid-Refractory Acute Graft Versus Host Disease
  Intervention:   Drug: T-Guard
  Sponsors:   Xenikos;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
  Recruiting
• ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

  NCT04006652

  Conditions:   Acute Graft Versus Host Disease;   Haploidentical Hematopoietic Stem Cell Transplant
  Intervention:   Drug: ApoGraft
  Sponsors:   Washington University School of Medicine;   Cellect Biotechnology
  Not yet recruiting
• Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

  NCT03721965

  Condition:   Acute Graft-versus-host Disease
  Interventions:   Drug: Itacitinib;   Drug: Corticosteroids
  Sponsor:   Incyte Corporation
  Recruiting
• Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

  NCT01521039

  Conditions:   Acute Graft-versus-Host Disease;   Allogeneic Stem Cell Transplant
  Intervention:   Procedure: Blood samples
  Sponsor:   Ohio State University Comprehensive Cancer Center
  Recruiting
• Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

  NCT04059757

  Condition:   Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
  Intervention:   Biological: Fecal Microbiota Transplantation (FMT)
  Sponsor:   Leland Metheny
  Not yet recruiting
• UCMSCs as Front-line Approach of Treatment for Patients With aGVHD

  NCT03847844

  Condition:   Acute-graft-versus-host Disease
  Interventions:   Biological: Umbilical cord derived mesenchymal stem cell;   Other: Placebo
  Sponsors:   Cytopeutics Sdn. Bhd.;   Universiti Tunku Abdul Rahman;   Ministry of Energy, Science, Technology, Environment and Climate Change, Malaysia
  Recruiting
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

  NCT03491215

  Condition:   Acute Graft Versus Host Disease
  Intervention:   Drug: Ruxolitinib
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• FMT In High-Risk Acute GVHD After ALLO HCT

  NCT04139577

  Conditions:   Acute Graft-Versus-Host Disease (Gvhd) Grade;   Hematopoietic Cell Transplantation;   Fecal Microbiota Transplant
  Intervention:   Biological: Fecal Microbiota Transplant
  Sponsors:   Massachusetts General Hospital;   American Cancer Society, Inc.
  Not yet recruiting
• Clinical Trial With MSC for Graft Versus Host Disease Treatment

  NCT02687646

  Condition:   Acute Graft Versus Host Disease
  Intervention:   Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.
  Sponsors:   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud;   Andalusian Initiative for Advanced Therapies
  Recruiting
• Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease

  NCT03214289

  Conditions:   Stem Cell Transplant Complications;   Graft Versus Host Disease, Acute;   Fecal Microbiota Transplantation
  Intervention:   Biological: Fecal Microbiota Transplantation
  Sponsor:   Sheba Medical Center
  Recruiting
• CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

  NCT03605927

  Conditions:   Graft-versus-host-disease;   GVHD;   GVHD, Acute
  Interventions:   Drug: BMS-986004;   Drug: Sirolimus;   Drug: Tacrolimus
  Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
  Recruiting
• Fecal Microbiota Transplantation in Gut aGVHD Treated

  NCT03148743

  Condition:   Acute-graft-versus-host Disease
  Intervention:   Biological: Fecal microbiota
  Sponsor:   The First Affiliated Hospital of Soochow University
  Recruiting
• Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease

  NCT01795573

  Condition:   Graft Versus Host Disease
  Intervention:   Biological: Cultured Treg cells
  Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
  Recruiting
• Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

  NCT03862079

  Condition:   Graft-versus-host Disease Prevention
  Interventions:   Other: Best Practice;   Procedure: Fecal Microbiota Transplantation;   Drug: Nystatin;   Drug: Piperacillin-Tazobactam
  Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
  Not yet recruiting
• Ruxolitinib and Steroid as First Line Therapy for Acute GVHD

  NCT03701698

  Condition:   Acute GVHD
  Interventions:   Drug: Ruxolitinib Oral Tablet;   Drug: Methylprednisolone
  Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  Not yet recruiting
• Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease

  NCT03492502

  Condition:   Fecal Microbiota Transplantation in Graft vs. Host Disease
  Intervention:   Biological: Autologous Fecal Microbiota Transplantation
  Sponsor:   Rambam Health Care Campus
  Not yet recruiting
• Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

  NCT04112810

  Condition:   Hematologic Malignancies
  Intervention:   Drug: Tildrakizumab
  Sponsor:   Medical College of Wisconsin
  Not yet recruiting
• Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

  NCT04070781

  Conditions:   Steroid Refractory GVHD;   Graft Vs Host Disease
  Interventions:   Drug: Itacitinib;   Drug: Tocilizumab
  Sponsors:   Columbia University;   Incyte Corporation
  Not yet recruiting
• To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids

  NCT03371667

  Conditions:   Allogeneic Disease;   GVH - Graft Versus Host Reaction;   GVHD, Acute;   Stem Cell Transplant Complications
  Interventions:   Drug: Methotrexate;   Drug: Placebo
  Sponsor:   Assistance Publique - Hôpitaux de Paris
  Recruiting
• PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

  NCT03689465

  Condition:   Hematopoietic Stem Cell Transplantation
  Interventions:   Drug: ATG;   Drug: CTX;   Drug: Mycophenolate Mofetil;   Drug: Ciclosporin A (CsA);   Drug: methotrexate (MTX)
  Sponsor:   Nanfang Hospital of Southern Medical University
  Recruiting
• Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

  NCT02828878

  Condition:   Hematological Malignancies
  Intervention:   Biological: Allogeneic MPBC transplantation from matched related donor
  Sponsor:   Cellect Biotechnology
  Recruiting
• Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

  NCT03057054

  Condition:   Malignant Neoplasm
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Lactobacillus plantarum strain 299;   Biological: Lactobacillus plantarum strain 299v;   Other: Placebo
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

  NCT03657160

  Condition:   Hematopoietic Stem Cells
  Interventions:   Drug: Vedolizumab;   Drug: Vedolizumab Placebo
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• CD24Fc for the Prevention of Acute GVHD Following Myeloablative HSCT

  NCT04095858

  Conditions:   Hematopoietic Stem Cell Transplantation;   Acute Graft Versus Host Disease;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes
  Interventions:   Drug: CD24Fc;   Drug: Placebo;   Drug: Methotrexate;   Drug: Tacrolimus
  Sponsor:   OncoImmune, Inc.
  Not yet recruiting
• A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

  NCT03763318

  Conditions:   Acute-graft-versus-host Disease;   aGVHD;   GVHD;   GVHD, Acute
  Interventions:   Biological: EQ001;   Biological: EQ001 Placebo
  Sponsors:   Equillium;   Biocon Limited
  Recruiting
• Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

  NCT00603330

  Conditions:   Graft-versus-host Disease;   Poor Graft Function;   Low Donor T-cell Chimerism
  Intervention:   Biological: Mesenchymal stem cells
  Sponsors:   University of Liege;   KU Leuven;   Maastricht University Medical Center;   Ziekenhuis Netwerk Antwerpen (ZNA);   University Hospital, Antwerp;   University Hospital, Ghent;   AZ-VUB;   AZ Sint-Jan AV;   Cliniques universitaires Saint-Luc- Université Catholique de Louvain;   University Hospital of Mont-Godinne;   Jolimont Hospital Haine Saint Paul;   Queen Fabiola Children's University Hospital
  Recruiting
• Phase II Trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT

  NCT02663622

  Conditions:   Graft Versus Host Disease;   Hematopoietic Stem Cell Transplantation;   Leukemia
  Interventions:   Drug: CD24Fc;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Placebo
  Sponsors:   OncoImmune, Inc.;   Ohio State University;   University of Michigan Rogel Cancer Center;   Indiana University School of Medicine;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
  Recruiting
• BMT Autologous MSCs for GvHD

  NCT02359929

  Conditions:   Graft Versus Host Disease;   Acute Graft Versus Host Disease;   Chronic Graft Versus Host Disease
  Intervention:   Biological: Autologous mesenchymal stromal cells (MSCs)
  Sponsors:   Emory University;   CURE Foundation
  Recruiting
• Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

  NCT02525029

  Condition:   Graft vs Host Disease
  Intervention:   Drug: Pregnyl®
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton

  NCT02737306

  Condition:   Graft Vs Host Disease
  Intervention:   Drug: PRO 140
  Sponsors:   CytoDyn, Inc.;   Amarex Clinical Research
  Recruiting
• Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

  NCT01903473

  Conditions:   Chronic Graft-Versus-Host Disease;   Acute Graft-Versus-Host Disease;   Steroid Refractory Graft-Versus-Host Disease
  Interventions:   Drug: Rapamycin;   Other: T regulatory cells
  Sponsor:   University of Liege
  Recruiting
• Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

  NCT02611180

  Conditions:   Acute Graft-versus-host Disease;   Acute GVHD;   Chronic Graft-versus-host Disease;   Chronic GVHD
  Interventions:   Procedure: Skin punch biopsy;   Procedure: Peripheral blood draw
  Sponsor:   Washington University School of Medicine
  Recruiting
• Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease (GvHD) After Allogenic Stem-cell Transplantation (HSCT)

  NCT04118556

  Condition:   GVHD, Acute
  Interventions:   Biological: Decidua Stroma Cells (DSC);   Drug: Best available Treatment (BAT)
  Sponsors:   Mats Remberger;   The Swedish Research Council
  Not yet recruiting
• Itacitinib for Low Risk GVHD

  NCT03846479

  Conditions:   Low Risk Acute Graft-versus-host Disease;   Graft-versus-host-disease;   GVHD
  Intervention:   Drug: Itacitinib
  Sponsor:   John Levine
  Recruiting
• First Line Therapy for High Risk Acute GVHD

  NCT04061876

  Conditions:   aGVHD;   Stem Cell Transplant Complications
  Interventions:   Drug: Ruxolitinib;   Drug: Corticosteroid
  Sponsor:   Chinese PLA General Hospital
  Recruiting
• Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer

  NCT03359980

  Condition:   Fecal Microbiota Transplantation
  Intervention:   Drug: fecal microbiota transfer
  Sponsor:   MaaT Pharma
  Recruiting
• RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

  NCT04014790

  Conditions:   Graft Vs Host Disease;   Graft-versus-host-disease;   Acute-graft-versus-host Disease;   Prevention of aGVHD
  Interventions:   Drug: RGI-2001;   Drug: Standard of Care
  Sponsor:   Regimmune Corporation
  Recruiting
• Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

  NCT03924401

  Condition:   Graft Versus Host Disease
  Intervention:   Drug: Abatacept
  Sponsors:   Emory University;   Thrasher Research Fund;   Sickle Cell Transplant Advocacy & Research Alliance (STAR)
  Recruiting
• Gut Decontamination In Pediatric Allogeneic Hematopoietic

  NCT02641236

  Conditions:   Hematopoietic Stem Cell Transplantation (HSCT);   Acute GVH Disease
  Intervention:   Drug: Vancomycin-polymyxin B
  Sponsor:   Dana-Farber Cancer Institute
  Recruiting
• Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

  NCT04167514

  Condition:   Graft Versus Host Disease (GVHD)
  Interventions:   Biological: Alpha-1 antitrypsin (AAT);   Drug: Placebo
  Sponsors:   CSL Behring;   Blood and Marrow Transplant Clinical Trials Network;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
  Not yet recruiting
• Neihulizumab for Standard-Risk Acute GVHD

  NCT04144036

  Condition:   Graft-versus-host Disease
  Intervention:   Drug: Neihulizumab
  Sponsor:   Sameem M. Abedin, MD
  Not yet recruiting
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

  NCT03434730

  Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
  Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
  Sponsor:   Memorial Sloan Kettering Cancer Center
  Recruiting
• TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

  NCT04033627

  Conditions:   Relapsed Pediatric ALL;   Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis);   Relapsed Pediatric AML
  Intervention:   Procedure: In Vitro T cells depletion using CliniMCAS system
  Sponsors:   Shanghai Children's Medical Center;   Nanfang Hospital of Southern Medical University;   Children's Hospital Of Soochow University;   Chinese University of Hong Kong;   Miltenyi Biotec GmbH
  Not yet recruiting
• An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

  NCT03840512

  Condition:   Prevention aGVHD
  Intervention:   Drug: CBD
  Sponsor:   Kalytera Therapeutics Israel, Ltd.
  Recruiting
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

  NCT01951885

  Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
  Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
  Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• MSC for Severe aGVHD

  NCT03631589

  Condition:   Steroid-resistant Severe aGVHD
  Intervention:   Biological: MSCs
  Sponsor:   Fujian Medical University
  Recruiting
• Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

  NCT02338232

  Condition:   GVHD
  Intervention:   Drug: Telmisartan
  Sponsor:   Hackensack Meridian Health
  Recruiting
• Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

  NCT03887156

  Conditions:   Acute Myeloid Leukemia in Remission;   Lymphoma in Remission;   Non-progressive Myeloproliferative Syndrome;   Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts;   Acute Leukemia Biphenotypic in Remission;   Acute Lymphoblastic Leukemia
  Intervention:   Diagnostic Test: Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
  Sponsors:   Assistance Publique - Hôpitaux de Paris;   SATT;   SNC Graft Versus Host Disease;   Imagine Institute;   AXONAL-BIOSTATEM;   CERBA laboratory
  Not yet recruiting
• Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

  NCT02743351

  Conditions:   Hematologic Malignancies;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Acute Graft-versus-host Disease
  Interventions:   Biological: ProTmune;   Biological: Control Arm
  Sponsor:   Fate Therapeutics
  Recruiting
• Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

  NCT03557749

  Conditions:   Immune and Microbial Reconstitution;   Systemic Viral Infection;   Acute-graft-versus-host Disease;   Chronic Graft-versus-host-disease;   Recurrent Malignancy;   Cytokine Release Syndrome;   Allogenic Related Donors;   Cell Therapy/Immunotherapy Patients
  Interventions:   Diagnostic Test: Blood Sample;   Diagnostic Test: Stool Sample;   Diagnostic Test: Urine Sample;   Diagnostic Test: Bronchoalveolar Lavage (BAL) fluid;   Diagnostic Test: Gastrointestinal biopsy x 2-4;   Diagnostic Test: Skin biopsy;   Diagnostic Test: Skin, mouth, and/or ocular swab;   Diagnostic Test: Apheresis Product;   Diagnostic Test: Final cellular product
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

  NCT03082677

  Conditions:   Myeloid Hematologic Malignancy;   Lymphoid Hematologic Malignancy
  Intervention:   Drug: Ixazomib
  Sponsors:   Memorial Sloan Kettering Cancer Center;   Millennium: The Takeda Oncology Company
  Recruiting
• Fecal Microbiota Transplantation in aGvHD After ASCT

  NCT03819803

  Condition:   Graft Versus Host Disease in GI Tract
  Intervention:   Biological: Fecal microbiota transplantation
  Sponsor:   Medical University of Graz
  Recruiting
• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia

  NCT03970096

  Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Donor;   Lymphoblastic Lymphoma;   Mixed Phenotype Acute Leukemia
  Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs;   Drug: Methotrexate;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells;   Drug: Peripheral Blood Stem Cell
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

  NCT03263767

  Condition:   Graft Versus Host Disease
  Interventions:   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Full body irradiation;   Drug: Cyclophosphamide;   Other: stem cell transplantation;   Other: nuclear cells
  Sponsor:   Nantes University Hospital
  Recruiting
• Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation

  NCT03357159

  Condition:   Graft Versus Host Disease
  Interventions:   Drug: Cyclophosphamide;   Drug: anti-human T-lymphocyte immunoglobulin (ATLG)
  Sponsor:   Sheba Medical Center
  Recruiting
• Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia

  NCT03467386

  Conditions:   Acute Myeloid Leukemia;   Hematopoietic Cell Transplant Recipient
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

  NCT03529825

  Condition:   Microbial Colonization
  Intervention:   Drug: Rifaximin
  Sponsor:   Emory University
  Recruiting
• Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD

  NCT03812705

  Condition:   Hematopoietic and Lymphoid Cell Neoplasm
  Intervention:   Biological: fecal microbiome transplantation
  Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  Recruiting
• Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation

  NCT02985775

  Condition:   CMV Infection
  Intervention:   Biological: Donor-derived CMVpp65-specific T cells
  Sponsor:   Peking University People's Hospital
  Recruiting
• Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)

  NCT03148197

  Conditions:   Acute Myeloid Leukemia;   Graft-versus-host-disease;   Allogeneic Hematopoietic Stem Cell Transplantation;   Stem Cell Transplant Complications
  Intervention:  
  Sponsor:   University of Cologne
  Recruiting
• GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

  NCT02799147

  Conditions:   Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
  Interventions:   Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
  Sponsor:   St. Petersburg State Pavlov Medical University
  Recruiting
• TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

  NCT03959241

  Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplasia;   Lymphoma
  Interventions:   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide;   Drug: Mycophenolate Mofetil;   Drug: Cyclophosphamide
  Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI);   National Marrow Donor Program
  Recruiting
• Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

  NCT02416388

  Condition:   Acute Myeloid Leukemia (AML)
  Interventions:   Drug: Idarubicin;   Drug: Daunorubicin;   Drug: HD Cytarabine;   Drug: Cyclosporine;   Drug: Methotrexate;   Drug: Mycophenolic acid (MPA);   Drug: vosaroxin;   Drug: ID cytarabine
  Sponsor:   University Hospital, Angers
  Recruiting
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

  NCT03755414

  Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Disease
  Interventions:   Procedure: Stem cell transplantation;   Drug: Itacitinib;   Other: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT);   Other: Human Activity Profile
  Sponsors:   Washington University School of Medicine;   Incyte Corporation
  Recruiting
• Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  NCT03779854

  Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
  Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
  Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
  Recruiting
• Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

  NCT03066466

  Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
  Interventions:   Drug: Atorvastatin;   Drug: Methotrexate;   Drug: Tacrolimus
  Sponsor:   Loyola University
  Recruiting
• Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

  NCT03270748

  Condition:   Myeloid Malignancies
  Intervention:   Drug: GvHD prophylaxis
  Sponsor:   Gruppo Italiano Trapianto di Midollo Osseo
  Not yet recruiting
• Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

  NCT03336632

  Conditions:   Leukemia, Acute;   MDS
  Interventions:   Drug: Chidamide;   Drug: Cyclophosphamide;   Drug: cyclosporine A
  Sponsor:   Sichuan University
  Not yet recruiting
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

  NCT03128359

  Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
  Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

  NCT03192397

  Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
  Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
  Recruiting
• A Phase 1 Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  NCT03802695

  Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Acute Leukemia
  Intervention:   Biological: OrcaGraft
  Sponsor:   Orca Biosystems, Inc.
  Recruiting
• Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

  NCT03434704

  Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection
  Interventions:   Drug: Conditioning treatment "Thiotepa-Treosulfan-Fludarabine";   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis
  Sponsor:   Ciceri Fabio
  Recruiting
• Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Unrelated Donor Blood and Marrow Transplantation

  NCT03842696

  Conditions:   Hematologic Diseases;   Acute Myeloid Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia - Chronic Phase;   Chronic Myelogenous Leukemia, Accelerated Phase;   Chronic Myelogenous Leukemia, Blastic Phase;   Myelodysplastic Syndromes;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Non Hodgkin Lymphoma;   Graft Vs Host Disease;   Graft-versus-host-disease
  Interventions:   Drug: Vorinostat;   Procedure: Blood and Marrow Transplant (BMT);   Drug: Tacrolimus;   Drug: Methotrexate
  Sponsor:   University of Michigan Rogel Cancer Center
  Recruiting
• Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

  NCT03963024

  Conditions:   Irradiated Bone Marrow;   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Multiple Myeloma;   Graft Vs Host Disease
  Interventions:   Drug: Conditioning treatment "Treosulfan-TMI";   Procedure: SCT;   Drug: GvHD prophylaxis
  Sponsor:   IRCCS San Raffaele
  Recruiting